CClinicalTrials.gg
CompletedNCT06444698Updated Feb 24, 2025

The Effect of Quinoa on Strength, VO2max and Athletic Performance

An interventional study of cookies that contain 50 grams of quinoa and cookies without quinoa in Sports Nutrition, sponsored by Imam Abdulrahman Bin Faisal University. Completed at 1 site in Saudi Arabia. Open to male participants aged 15 Years to 18 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-24.

Sponsored by Imam Abdulrahman Bin Faisal University · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
32
Allocation
Not applicable
Ages
15 Years to 18 Years
Sex
Male
01

Study summary

Background: Proper nutrition is essential for sports performance. Quinoa is a gluten-free grain rich in macronutrients such as protein, polysaccharides, and fatty acids and consists of many phytochemicals such as carotenoids, flavonoids, saponins, fiber, vitamins, and minerals. Phytochemicals in quinoa act as antioxidant and anti-inflammatory. This will protect against several oxidative stress related diseases.

Objective: Investigate the effect of 50 g of quinoa for four weeks on muscle strength, VO2max and athletic performance among adolescent athletes.

Study design: A Double blinded randomized control trial with pre-test and post-test design.

Methods :32 subjects will be included in this trial. Subjects will be divided randomly into control and experimental group with a 1:1 ratio; the experimental group will receive two cookies that contain 50 grams of quinoa; the control group will receive the same two cookies that but without quinoa. Strength will be assessed by using hand-held dynamometer (HHD). Maximum oxygen uptake capacity (Vo2max) will be assessed by Queen's College step test (QCT). And for evaluating performance: standing long jump test, ball throw test, and agility T-test will be used. Subjects will be asked to take the cookies 1-4 hours before bedtime daily during the study period.

Statistical Analysis: Shapiro wilk test will be performed to check the normality of the data and Levenes test will be performed to check homogeneity of variance. Cohen's d will be used to check the effect size. The level of significance is set to p ≤ 0.05.

02

Conditions studied

  • Sports Nutrition
03

In context

Lead sponsor

Imam Abdulrahman Bin Faisal University is the lead sponsor of 88 studies on the registry; 14 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
15 Years to 18 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Inclusion criteria

1- Healthy adolescent male athletes aged 15 to 18

Exclusion criteria

Exclusion criteria:

1- Use any dietary supplementation, including protein powder, during the study period.

  1. Musculoskeletal, neurological, cardiovascular, or systemic disorders which may affect the testing as reported by the participants
  1. Biomechanical abnormalities which may affect the testing as reported by the participants
  1. Participants psychological disorders
  1. Participants on medication which may affect the measurements as reported by the participants
  1. Allergic from any recipe ingredients
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
32 participants (actual)

Study arms

  • Experimental
    Experimental group

    the experimental group will receive two cookies that contain 50 grams of quinoa

    Dietary Supplement: cookies that contain 50 grams of quinoa

  • Placebo comparator
    Control group

    control group will receive the same two cookies that but without quinoa

    Dietary Supplement: cookies without quinoa

Interventions

  • Dietary supplementcookies that contain 50 grams of quinoa

    250 grams of ground quinoa will be mixed with 250 grams of ready-to-use cookie flour and 100 gram of butter, one egg, and 75 gram of chocolate chips will be added. After mixing, the ingredients will be divided into (10) cookies (each cookie will continue 25 grams of quinoa) and bake them in oven for 9-11 mint at 190 °C. The placebo control group will receive cookies that continue the same ingredient but without quinoa and the cookies will look like the experimental group cookies. Cookies delivery will be every 3 to 4 days for each participants.

  • Dietary supplementcookies without quinoa

    The placebo control group will receive cookies that continue the same ingredient of experimental group but without quinoa and the cookies will look like the experimental group cookies.

06

What researchers measure

Primary outcomes

  1. strength of the biceps and triceps by Hand held dynameter

    Time frame: base line measurement and post test after 4 weeks of intervention

  2. Maximum oxygen uptake capacity (Vo2max) assessed by Queen's College Step Test (QCT)

    Time frame: base line measurement and post test after 4 weeks of intervention

  3. standing long jump test

    Time frame: base line measurement and post test after 4 weeks of intervention

  4. Ball throw test

    Time frame: base line measurement and post test after 4 weeks of intervention

  5. Agility T-test

    Time frame: base line measurement and post test after 4 weeks of intervention

07

Study locations

1 site
  • Imam abdulrahman bin faisal university
    Dammam, 34521, Saudi Arabia
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06444698
Lead sponsor
Imam Abdulrahman Bin Faisal University
Responsible party
Shibili Nuhmani (Assistant Professor, Imam Abdulrahman Bin Faisal University) — Principal investigator
First posted
Jun 5, 2024
Start date
Jul 25, 2024
Primary completion
Sep 25, 2024
Completion
Oct 10, 2024
Last update
Feb 24, 2025

Study contacts

Shibili Nuhmani, PhD
principal investigator · Imam Abdulrahman Bin Faisal University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion